<unk>  has a number of clinically significant interactions. The concomitant use of<unk>  and monoamine oxidase inhibitors (MAOIs, such as selegiline) is not indicated, as it may increase the risk of serotonin syndrome, a somewhat rare but serious adverse drug reaction.<unk>  should not be taken within two weeks of stopping or starting an MAOI. Taking both<unk>  and certain medications used in the treatment of migraines—such as ergolines and triptans—as well as opioids, may also increase the risk for serotonin syndrome, as may the use of more than one serotonin reuptake inhibitor at the same time. The concomitant use of<unk>  and drugs which inhibit CYP3A4, such as ketoconazole and erythromycin, may increase plasma levels of<unk> .<unk>  does not affect the efficacy of hormonal contraception.
Sibutramine
Lofepramine
Quinupramine
Mitapivat
Metapramine
Nyasol
Tasimelteon
Pipotiazine